Methods for Treatment of Insulin-Like Growth Factor-1 Deficiency
AssigneeTercica, Inc.
InventorsRoss G. Clark, Gillian Clark
Life of this patent
Estimating the term…
Abstract
The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day.
Claims19
-65. (canceled)
A method for treating a human pediatric subject having primary insulin-like growth factor-1 deficiency (IGFD) comprising;
- administering to a human pediatric subject suffering from a growth disorder characterized by primary IGFD and partial endogenous growth hormone signaling a combination of an amount of insulin like growth factor-1 (IGF-1) and an amount of growth hormone (GH) effective to promote growth in the subject, wherein the subject is further characterized as follows:
- the subject, at the time of treatment or prior to initial treatment with IGF-1, has or had a height at least about 2.0 standard deviations (SD) below a normal mean for a subject of the same age and gender, and
- the subject has moderate primary IGFD but not severe primary IGFD,
- wherein the subject receives each of IGF-1 and GH in a single administration per day, and wherein the single administration of IGF-1 and the single administration of GH are administered to the patient substantially contemporaneously each day.
Dependencies are inferred from the claim text.